"Immunosuppressive Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
Descriptor ID |
D007166
|
MeSH Number(s) |
D27.505.696.477.656
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunosuppressive Agents".
Below are MeSH descriptors whose meaning is more specific than "Immunosuppressive Agents".
This graph shows the total number of publications written about "Immunosuppressive Agents" by people in this website by year, and whether "Immunosuppressive Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1997 | 0 | 1 | 1 |
1998 | 0 | 2 | 2 |
2000 | 0 | 1 | 1 |
2001 | 4 | 0 | 4 |
2002 | 6 | 2 | 8 |
2003 | 9 | 10 | 19 |
2004 | 5 | 6 | 11 |
2005 | 14 | 8 | 22 |
2006 | 5 | 6 | 11 |
2007 | 10 | 9 | 19 |
2008 | 6 | 4 | 10 |
2009 | 11 | 7 | 18 |
2010 | 3 | 7 | 10 |
2011 | 10 | 2 | 12 |
2012 | 9 | 9 | 18 |
2013 | 8 | 4 | 12 |
2014 | 10 | 7 | 17 |
2015 | 1 | 9 | 10 |
2016 | 4 | 7 | 11 |
2017 | 4 | 6 | 10 |
2018 | 3 | 1 | 4 |
2019 | 6 | 3 | 9 |
2020 | 2 | 5 | 7 |
2021 | 1 | 4 | 5 |
2022 | 2 | 4 | 6 |
2023 | 0 | 2 | 2 |
2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunosuppressive Agents" by people in Profiles.
-
Gupta M, Yadav A. Reproductive Health in Kidney Transplant Recipients. Adv Kidney Dis Health. 2024 Sep; 31(5):466-475.
-
Dalakas MC. Advances in the therapeutic algorithm for myasthenia gravis. Nat Rev Neurol. 2023 Jul; 19(7):393-394.
-
Kalatskaya I, Giovannoni G, Leist T, Cerra J, Boschert U, Rolfe PA. Revealing the immune cell subtype reconstitution profile in patients from the CLARITY study using deconvolution algorithms after cladribine tablets treatment. Sci Rep. 2023 May 18; 13(1):8067.
-
Stefano N, Sormani MP, Giovannoni G, Rammohan K, Leist TP, Coyle PK, Dangond F, Alexandri N, Galazka A. Relapses in people with multiple sclerosis treated with cladribine tablets followed for up to 5?years: a plain language summary. Neurodegener Dis Manag. 2022 12; 12(6):303-310.
-
Zorzetti N, Lauro A, Khouzam S, Marino IR. Immunosuppression, Compliance, and Tolerance After Orthotopic Liver Transplantation: State of the Art. Exp Clin Transplant. 2022 03; 20(Suppl 1):3-9.
-
Hissong E, Mostyka M, Yantiss RK. Histologic Features of Tacrolimus-induced Colonic Injury. Am J Surg Pathol. 2022 01 01; 46(1):118-123.
-
Donovan R, Eisen H, Ali O. Antiproliferatives and Transplantation. Handb Exp Pharmacol. 2022; 272:39-52.
-
Wang D, Eisen HJ. Mechanistic Target of Rapamycin (mTOR) Inhibitors. Handb Exp Pharmacol. 2022; 272:53-72.
-
Konda P, Golamari R, Eisen HJ. Novel Immunosuppression in Solid Organ Transplantation. Handb Exp Pharmacol. 2022; 272:267-285.
-
Ravindranath MH, El Hilali F, Filippone EJ. The Impact of Inflammation on the Immune Responses to Transplantation: Tolerance or Rejection? Front Immunol. 2021; 12:667834.